Pfizer articles
-
Pfizer Sees Less Revenue From Covid-19 Treatments, Stock Faces Headwinds Ahead Of Q1 Earnings - Pfizer (N
Pfizer's Q1 earnings report expects EPS of 49 cents and $13.09 billion in revenues. Stock has declined 34.61% YoY and -10.94% YTD due to COVID-19 revenue decrease. Technical analysis shows bearish trend with potential for further downside.
-
Pfizer Reports First-Quarter 2024 Results
NEW YORK, May 01, 2024--Pfizer Inc. (NYSE: PFE) reported financial results for the first quarter of 2024 and raised its Adjusted(3) diluted EPS guidance while maintaining all other components of its 2024 financial guidance(6).
-
BMO Capital Markets Reiterates “Outperform” Rating for Pfizer (NYSE:PFE)
Pfizer (NYSE:PFE – Get Free Report)‘s stock had its “outperform” rating reiterated by research analysts at BMO Capital Markets in a research report issued to clients and investors on Thursday, Benzinga reports. They currently have a $36.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $33.00. BMO Capital Markets’ […]